Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma.

  title={Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma.},
  author={David J. Panka and Michael B. Atkins and James Walter Mier},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  volume={12 7 Pt 2},
The mitogen-activated protein kinase (MAPK; i.e., Ras-Raf-Erk) pathway is an attractive target for therapeutic intervention in melanoma due to its integral role in the regulation of proliferation, invasiveness, and survival and the recent availability of pharmaceutical agents that inhibit the various kinases and GTPases that comprise the pathway. Genetic studies have identified activating mutations in either B-raf or N-ras in most cutaneous melanomas. Other studies have delineated the… CONTINUE READING

From This Paper

Topics from this paper.
46 Citations
31 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 46 extracted citations


Publications referenced by this paper.
Showing 1-10 of 31 references

SPRY2 is an inhibitor of the Ras/extracellular signalregulated kinasepathway inmelanocytes andmelanoma cells with wild type BRAF but not with theV599E mutant

  • D Tsavachidou, ML Coleman, G Athanasiadis
  • Cancer Res
  • 2004
Highly Influential
13 Excerpts

Mutations of the BRAFgene inhumancancer.Nature 2002;417:949^54

  • H Davies, GR Bignell, C Cox
  • 2002
Highly Influential
13 Excerpts

BAY 43 - 9006 induces apoptosis in melanoma cell lines

  • O Yamaguchi, WatanabeT, K Nishida
  • Proc Am Assoc Cancer Res
  • 2005

Role of the kinaseMST 2 in suppressionof apoptosis by the proto - oncogene product Raf - 1

  • JH Lin, A Makris, C McMahon
  • Science
  • 2004

Similar Papers

Loading similar papers…